Zhixiang Bio has filed its IPO prospectus, planning to list in Hong Kong, with Dongxing Securities as the sole sponsor.

On June 1, 2026, Intellective Biologics (Suzhou) Co., Ltd. (hereinafter referred to as "Intellective Biologics"), headquartered in Changshu City, Suzhou, Jiangsu Province, filed a prospectus with the Hong Kong Stock Exchange, proposing a listing on the Hong Kong Main Board. Founded in 2018, Intellective Biologics is a leading China-based, manufacturing-driven, full-lifecycle Contract Development and Manufacturing Organization (CDMO) that provides end-to-end CDMO solutions for the development and production of biologics. According to Frost & Sullivan data: as of 202

Ryanben CapitalJun 2 14:13

New Listing News | Zhixiang Bio has filed an application with the Hong Kong Stock Exchange, being China's second-largest biologics CDMO company.

According to a disclosure by the Hong Kong Stock Exchange on June 1, Zhixiang Bio (Suzhou) Co., Ltd. has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with DX Securities (Hong Kong) acting as its sole sponsor.

Zhitong FinanceJun 1 21:36